Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals ...
Madrigal Pharmaceuticals MDGL reported first-quarter 2025 loss of $3.32 per share, narrower than the Zacks Consensus Estimate of a loss of $3.62. In the year-ago quarter, the company had incurred a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results